Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?

Corey J. Langer, Heather Wakelee, Joan Schiller, Hak Choy, Frances Shepherd, Everett E. Vokes, Alex A. Adjei, Paul Baas, Nagahiro Saijo, David R Gandara

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Combined-modality therapy has emerged as the standard of care for fit patients with unresectable, locally advanced non-small-cell lung cancer (NSCLC). Concurrent chemotherapy/radiation has demonstrated therapeutic superiority compared with sequential or asynchronous chemotherapy and radiation in this setting. The role of consolidation or maintenance therapy with targeted agents or conventional cytotoxic agents remains unclear. We explore the portfolio of clinical trials being conducted in locally advanced NSCLC by North American cooperative oncology groups as well as ongoing trials in Europe and Japan. These efforts focus on radiation dose escalation using image-guided radiation therapy as well as newer cytotoxic agents (eg, pemetrexed) and targeted therapies (eg, cetuximab, bevacizumab, and etc) thus far unexplored in this setting.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalClinical Lung Cancer
Volume9
Issue number2
DOIs
StatePublished - Mar 2008

Keywords

  • Cetuximab
  • Chemoradiation therapy
  • Etoposide
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?'. Together they form a unique fingerprint.

  • Cite this

    Langer, C. J., Wakelee, H., Schiller, J., Choy, H., Shepherd, F., Vokes, E. E., Adjei, A. A., Baas, P., Saijo, N., & Gandara, D. R. (2008). Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress? Clinical Lung Cancer, 9(2), 85-91. https://doi.org/10.3816/CLC.2008.n.013